Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products, is congratulating its colead scientific research collaborator Professor Dr. Dirk Görlich, who is this year’s Louis-Jeantet Prize recipient. A director at the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”), Görlich and his colleague Dr. Matthias Dobbelstein, from the University Medical Center Göttingen (“UMG”), lead teams that have collaborated with Scinai in the discovery of nanosized VHH antibodies (NanoAbs). These NanoAbs form the basis of Scinai’s innovative, derisked pipeline. In announcing the award, MPI-NAT noted that Görlich received the recognition for “discovering a new kind of biological matter that acts as a highly selective barrier to control central transport pathways in the cell” as well as his “groundbreaking contributions to our understanding of the processes by which macromolecules are transported into and out of the cell nucleus.”
The Louis-Jeantet Prize was established in 1986 and is worth $576,000; it is awarded annually to European-based researchers in recognition of groundbreaking work in the field of biomedicine. Görlich has received other prestigious awards including the Heinz Maier-Leibnitz Prize, the EMBO Gold Medal, the Alfried Krupp Prize, the WLA Prize 2022 and the Animal Welfare Research Prize of the German Federal Ministry of Food and Agriculture. “On behalf of Scinai’s team, I offer sincere congratulations to Dirk on being awarded the 2024 Louis-Jeantet Prize,” said Scinai Immunotherapeutics CEO Amir Reichman in the press release. “The award provides significant evidence of the creativity, professionalism, and elite scientific acumen of the scientist leading the discovery of our pipeline of innovative NanoAb-based therapeutic products.”
To view the full press release, visit https://ibn.fm/6Z8F1
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics is a biopharmaceutical company with two complementary business units: one focused on in-house development of inflammation and immunology (“I&I”) biological products beginning with an innovative, derisked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO (“CDMO”) providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early stage biotech companies. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.InvestorWire.com
InvestorWire is powered by IBN